Clinical features of anti-mitochondrial M2 antibody-positive myositis : case series of 17 patients

Nagai, Azusa; Nagai, Toshiyuki; Yaguchi, Hiroaki; Fujii, Shintaro; Uwatoko, Hisashi; Shirai, Shinichi; Horiuchi, Kazuhiro; Iwata, Ikuko; Matsushima, Masaaki; Ura, Shigehisa; Anzai, Toshihisa; Yabe, Ichiro

Clinical features of anti-mitochondrial M2 antibody-positive myositis : case series of 17 patients

Nagai, Azusa; Nagai, Toshiyuki; Yaguchi, Hiroaki et al.

Journal of the neurological sciences, 2022, 442, 120391

Permalink : https://hdl.handle.net/2115/90686

このアイテムのアクセス数:1,640件（2026-10-09 16:35 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数
JNS 442 120391	pdf	529 KB	914
Supplementary materia	xlsx	12.3 KB	271
Supplementary Table 1	xlsx	20.3 KB	132
Fig.1 A B C D E F	pdf	404 KB	238
Fig.2 A B C D	pdf	263 KB	146

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/90686
タイトル	Clinical features of anti-mitochondrial M2 antibody-positive myositis : case series of 17 patients
著者	Nagai, Azusa ; Nagai, Toshiyuki ; Yaguchi, Hiroaki ; Fujii, Shintaro ; Uwatoko, Hisashi ; Shirai, Shinichi ; Horiuchi, Kazuhiro ; Iwata, Ikuko ; Matsushima, Masaaki ; Ura, Shigehisa ; Anzai, Toshihisa ; Yabe, Ichiro
著者名 Nagai, Azusa
e-Rad_Researcher 00528218 著者名 Nagai, Toshiyuki
著者名 Yaguchi, Hiroaki
著者名 Fujii, Shintaro
著者名 Uwatoko, Hisashi
著者名 Shirai, Shinichi
著者名 Horiuchi, Kazuhiro
著者名 Iwata, Ikuko
著者名 Matsushima, Masaaki
著者名 Ura, Shigehisa
e-Rad_Researcher 60232089 著者名 Anzai, Toshihisa
e-Rad_Researcher 60372273 著者名 Yabe, Ichiro
言語	英語
キーワード	Anti-mitochondrial M2 antibody
	Myositis
	Inflammatory myopathy
	Weight loss
	Cardiac complication
	Respiratory failure
	Chronic clinical course
発行日	2022-11-15
出版者	Elsevier
収録物名	Journal of the neurological sciences
巻(号)	442
ページ	120391
抄録	Objective: In 2012, a large number of myositis cases with anti-mitochondrial M2 (AMA-M2) antibody, which had well been known as the serological hallmark for primary biliary cholangitis (PBC), were reported in Japan. Recently, some case series from Japan, France, America, China and India have shown that approximately 2.5% to 19.5% of patients with myositis have AMA-M2 antibody. The objective of this study was to clarify the prevalence, clinical features, treatment outcome, and severity determinants of AMA-M2 positive myositis. Methods: This study was a multicenter observational study. We enrolled patients who were diagnosed with myositis during a ten-year period between 2012 and 2021. Results: Of the total of 185 patients with inflammatory myopathy, 17 patients were positive for AMA-M2 anti-body. The typical symptoms were weakness mainly involving paravertebral muscles, weight loss, respiratory failure, and cardiac complications. Thirteen of the 17 patients had cardiac complications. A strong correlation was found between respiratory failure and modified Rankin Scale (mRS) score. A strong correlation was also found between respiratory failure and body weight, indicating that weight loss can be an indicator of potential progression of respiratory failure. Six of the 17 patients were complicated by malignancy. Conclusions: This study showed significant correlations between % vital capacity (VC), body mass index (BMI), and mRS score in patients with AMA-M2-positive myositis. Immunotherapy often improved CK level and res-piratory dysfunction. We therefore propose that %VC and BMI should be monitored as disease indicators in treatment of AMA-M2-positive myositis.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2022, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	0022-510X
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.jns.2022.120391